World Library  
Flag as Inappropriate
Email this Article
 

Bupivacaine

Bupivacaine (INN)
Systematic (IUPAC) name
(RS)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
Clinical data
Pronunciation
Trade names Marcaine, Marcain, Sensorcaine, and Vivacaine
AHFS/Drugs.com
Pregnancy
category
  • AU: A
Legal status
Routes of
administration
parenteral, topical
Pharmacokinetic data
Bioavailability n/a
Protein binding 95%
Metabolism Liver
Onset of action Within 15 min[1]
Biological half-life 3.5 hours (adults)
8.1 hours (neonates)
Duration of action 2 to 8 hr[2]
Excretion Kidney, 4–10%
Identifiers
CAS Registry Number  Y
ATC code N01
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  N
ChEMBL  Y
Chemical data
Formula C18H28N2O
Molecular mass 288.43 g/mol
Physical data
Melting point 107 to 108 °C (225 to 226 °F)
 N   

Bupivacaine, marketed under the brand name Marcaine among others, is a medication used to freeze tissue in a specific area.[1] It is used by injecting it into the area, around a nerve that supplies the area, or into the spinal canal's epidural space. It is available mixed with a small amount of epinephrine to make it last longer.[1] It typically begins working within 15 minutes and lasts for 2 to 8 hours.[1][2] Possible side effects include sleepiness, muscle twitching, ringing in the ears, changes in vision, low blood pressure, and an irregular heart rate. There are concerns that injecting it into a joint can cause problems with the cartilage. Concentrated bupivacaine is not recommended for epidural freezing. Epidural freezing may also increase the length of labor. It is a local anaesthetic of the amide group.[1] Bupivacaine was discovered in 1957.[3] It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.[4] Bupivacaine is available as a generic medication and is not very expensive.[1][5] The wholesale cost of a vial is about 2.10 USD.[6]

Contents

  • Medical uses 1
  • Contraindications 2
  • Adverse effects 3
    • Treatment of overdose 3.1
    • Pregnancy and lactation 3.2
  • Mechanism of action 4
  • Pharmacokinetics 5
  • Chemical structure 6
  • Cost 7
  • Research 8
  • References 9
  • External links 10

Medical uses

Bupivacaine is indicated for local infiltration, peripheral nerve block, sympathetic nerve block, and epidural and caudal blocks. It is sometimes used in combination with epinephrine to prevent systemic absorption and extend the duration of action. The 0.75% (most concentrated) formulation is used in retrobulbar block.[7] It is the most commonly used local anesthetic in epidural anesthesia during labor, as well as in postoperative pain management.[8]

Contraindications

Bupivacaine is contraindicated in patients with known hypersensitivity reactions to bupivacaine or amino-amide anesthetics. It is also contraindicated in obstetrical paracervical blocks and intravenous regional anaesthesia (Bier block) because of potential risk of tourniquet failure and systemic absorption of the drug and subsequent cardiac arrest. The 0.75% formulation is contraindicated in epidural anesthesia during labor because of the association with refractory cardiac arrest.[9]

Adverse effects

Compared to other local anaesthetics, bupivacaine is markedly cardiotoxic. However, adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs are caused by accelerated absorption from the injection site, unintentional intravascular injection, or slow metabolic degradation. However, allergic reactions can rarely occur.[9]

Clinically significant adverse events result from systemic absorption of bupivacaine and primarily involve the central nervous system (CNS) and cardiovascular system. CNS effects typically occur at lower blood plasma concentrations. Initially, cortical inhibitory pathways are selectively inhibited, causing symptoms of neuronal excitation. At higher plasma concentrations, both inhibitory and excitatory pathways are inhibited, causing CNS depression and potentially coma. Higher plasma concentrations also lead to cardiovascular effects, though cardiovascular collapse may also occur with low concentrations.[10] Adverse CNS effects may indicate impending cardiotoxicity and should be carefully monitored.[9]

Toxicity can also occur in the setting of subarachnoid injection during high spinal anesthesia. These effects include: parasthesia, paralysis, apnea, hypoventilation, fecal incontinence, and urinary incontinence. Additionally, bupivacaine can cause chondrolysis after continuous infusion into a joint space.[9]

Bupivacaine has caused several deaths when the epidural anaesthetic has been administered intravenously accidentally.[11]

Treatment of overdose

Animal evidence[12][13] indicates intralipid, a commonly available intravenous lipid emulsion, can be effective in treating severe cardiotoxicity secondary to local anaesthetic overdose, and human case reports of successful use in this way.[14][15] Plans to publicize this treatment more widely have been published.[16]

Pregnancy and lactation

Bupivacaine crosses the placenta and is a pregnancy category C drug. However, it is approved for use at term in obstetrical anesthesia. Bupivacaine is excreted in breast milk. Risks of discontinuing breast feeding versus discontinuing bupivacaine should be discussed with the patient.[9]

Mechanism of action

Bupivacaine binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, which prevents depolarization. Without depolarization, no initiation or conduction of a pain signal can occur.

Pharmacokinetics

The rate of systemic absorption of bupivacaine and other local anesthetics is dependent upon the dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the preparation.[17]

  • Onset of action (route and dose-dependent): 1-17 min
  • Duration of action (route and dose-dependent): 2-9 hr
  • Half life: neonates, 8.1 hr, adults: 2.7 hr
  • Time to peak plasma concentration (for peripheral, epidural or caudal block): 30-45 min
  • Protein binding: about 95%
  • Metabolism: hepatic
  • Excretion: renal (6% unchanged)[9]

Chemical structure

Like lidocaine, bupivacaine is an amino-amide anesthetic; the aromatic head and the hydrocarbon chain are linked by an amide bond rather than an ester as in earlier local anesthetics. As a result, the amino-amide anesthetics are more stable and less likely to cause allergic reactions. Unlike lidocaine, the terminal amino portion of bupivacaine (as well as mepivacaine, ropivacaine, and levobupivacaine) is contained within a piperidine ring; these agents are known as pipecholyl xylidines.[8]

Cost

Bupivacaine is available as a generic medication and is not very expensive.[1][5] The wholesale cost of a vial of bupivacaine is about 2.10 USD.[6]

Research

Levobupivacaine is the (S)-(–)-enantiomer of bupivacaine, with a longer duration of action, produces less vasodilation. Durect Corporation is developing a biodegradable controlled-release drug delivery system for after surgery. It has currently completed a phase-III clinical trial.[18]

References

  1. ^ a b c d e f g "Bupivacaine Hydrochloride". The American Society of Health-System Pharmacists. Retrieved Aug 1, 2015. 
  2. ^ a b Whimster, David Skinner (1997). Cambridge textbook of accident and emergency medicine. Cambridge: Cambridge University Press. p. 194.  
  3. ^ Egan, Talmage D. (2013). Pharmacology and physiology for anesthesia : foundations and clinical application. Philadelphia, PA: Elsevier/Saunders. p. 291.  
  4. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  5. ^ a b Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 22.  
  6. ^ a b "Bupivacaine HCL". International Drug Price Indicator Guide. Retrieved 29 August 2015. 
  7. ^ Lexicomp. "Bupivacaine (Lexi-Drugs)". Retrieved 20 April 2014. 
  8. ^ a b c Miller, Ronald D. (November 2, 2006). Basics of Anesthesia. Churchill Livingstone. 
  9. ^ a b c d e f g "Bupivacaine (Lexi-Drugs)". Retrieved 20 April 2014. 
  10. ^ Australian Medicines Handbook. Adelaide. 2006.  
  11. ^ ABS-CBN Interactive: Filipino nurse dies in UK due to wrong use of anaesthetic
  12. ^ Weinberg, GL; VadeBoncouer, T; Ramaraju, GA; Garcia-Amaro, MF; Cwik, MJ. (1998). "Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats". Anesthesiology 88 (4): 1071–5.  
  13. ^ Weinberg, G; Ripper, R; Feinstein, DL; Hoffman, W. (2003). "Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity". Regional Anesthesia and Pain Medicine 28 (3): 198–202.  
  14. ^ Rosenblatt, MA; Abel, M; Fischer, GW; Itzkovich, CJ; Eisenkraft, JB (July 2006). "Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest.". Anesthesiology 105 (1): 217–8.  
  15. ^ Litz, RJ; Popp, M; Stehr, S N; Koch, T. (2006). "Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion". Anaesthesia 61 (8): 800–1.  
  16. ^ Picard, J; Meek, T (February 2006). "Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob.". Anaesthesia 61 (2): 107–9.  
  17. ^ "bupivacaine hydrochloride (Bupivacaine Hydrochloride) injection, solution". FDA. Retrieved 20 April 2014. 
  18. ^ Bupivacaine Effectiveness and Safety in SABER™ Trial (BESST); http://clinicaltrials.gov/ct2/show/NCT01052012 ClinicalTrials.gov processed this record on February 29, 2012.

External links

  • RxList.com
  • Drugs.com
  • More on lipid rescue
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.